China released the 2022 NDRL list, Chinese pharma benefited from the list
- ipharmaservices
- Dec 4, 2021
- 1 min read
Updated: Dec 8, 2021
China has released the 2021 Drug catalog, which included 2,860 drugs, out of which 1,486 drugs are Western drugs.
Reuters reported a nearly 60% price cut for 67 products. These products include Lilly's Taltz and Janssen's Darzalex.
BeiGene's tislelizumab, Jiangsu Hengrui Medicine's camrelizumab, and Junshi Biosciences' toripalimab slashed prices by 80% to get included in the NDRL.
InnoCare's orelabrutinib was included in the list for treating r/r chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL), and mantle cell lymphoma (MCL)
BeiGene's tislelizumab is included for patients with
non-squamous non-small cell lung cancer (NSCLC) as first-line therapy in combination with pemetrexed and platinum chemotherapy for patients (EGFR negative and ALK-negative cancers)
hepatocellular carcinoma previously treated with systemic therapy
urothelial carcinoma with PD-L1 high expression
Hodgkin's lymphoma (cHL) was treated with two systemic treatments previously
Brukinsa is included for treating Waldenström's macroglobulinemia (WM), mantle cell lymphoma (MCL), chronic lymphocytic leukemia (CLL) /small lymphocytic lymphoma (SLL). Pamiparib is included in NDRL for treating ovarian, fallopian tube, or primary peritoneal cancer.
RemGen's telitacicept for systemic lupus erythematosus and disitamab vedotin for gastric cancer is included in NDRL
Asclevir (ravidasvir)/ Ganovo (danoprevir) regimen was included for treating HCV patients.
The list can be available from here:
Comments